Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kaitong Buzu Re granules
- Development stage
- Phase 2
- Lead developer
- Xinjiang Uygur Autonomous Region Institute of Drug Research
- Administration
- Oral
01
Overview
Kaitong Buzu Re granules is a traditional Chinese medicine (TCM) developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research. It is formulated as granules for oral administration and is primarily indicated for the treatment of acute hepatitis A, specifically targeting the liver–gallbladder damp-heat syndrome according to TCM diagnostic criteria. The drug has been evaluated in a randomized, double-blind, placebo-controlled Phase II clinical trial in China to assess its efficacy and safety in adult patients with acute hepatitis A.
- Other names
- Kaitong Buzu Re Granules
Beyond the preview
Go deeper on Kaitong Buzu Re granules.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kaitong Buzu Re granules.